• Amgen (NasdaqGS:AMGN) presented new VESALIUS-CV Phase 3 data for Repatha in high-risk diabetes at the ADA 86th Scientific Sessions in 2026.
• The trial reported a significant reduction in major cardiovascular events for high-risk diabetic patients treated with Repatha.
• Results were also published in major medical journals, underscoring clinical relevance for cardiometabolic care.
• The findings highlight a large, underserved patient group within diabetes and obesity management where current treatment uptake is limited.

For investors watching NasdaqGS:AMGN, this update adds a fresh angle to the story beyond oncology and IMDYLLTRA’s EU approval. Repatha already sits within Amgen’s established cardiovascular and metabolic portfolio, and these data place additional focus on the cardiometabolic segment of the business. The VESALIUS-CV readout relates directly to how Amgen is positioned in an area where diabetes, obesity and cardiovascular risk intersect.

The new outcomes data may influence how clinicians think about LDL lowering and event reduction in high-risk diabetic patients, which could affect future treatment patterns. For shareholders, the key questions now are how broadly guidelines and payers eventually respond and what that might mean for Repatha’s role within Amgen’s wider cardiometabolic lineup.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Investor Checklist

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$337.73, Amgen trades about 4.2% below the US$352.50 analyst target, within the typical 10% band.
• ✅ Simply Wall St Valuation: Shares are described as trading 49.2% below one DCF based fair value estimate, a sizeable discount signal.
• ✅ Recent Momentum: The stock is up 2.5% over the past 30 days, showing positive short term momentum into the ADA 2026 update.

There's only one way to know the right time to buy, sell or hold Amgen. Head to Simply Wall St's company report for the latest analysis of Amgen's Fair Value.

Key Considerations

• 📊 The new Repatha outcomes data gives Amgen another clinically relevant pillar in cardiometabolic care, adding depth alongside oncology and other franchises.
• 📊 Watch how guideline updates, payer coverage and cardiologist uptake evolve, as these factors will shape Repatha’s realised contribution within Amgen’s US$37.2b revenue base.
• ⚠️ Simply Wall St flags one major risk related to debt coverage by operating cash flow, so balance sheet strength remains an important cross check against the Repatha opportunity.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Amgen analysis. Alternatively, you can check out the community page for Amgen to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.